Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Renaissance Pharma","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renaissance Pharma Launches Today and Announces the In-Licensing of Hu14.18K322A (Hu14.18) from St. Jude Children\u2122s Research Hospital for the Treatment of High-Risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Renaissance Pharma","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Acquires Renaissance Pharma Ltd with its Clinical Stage Immunotherapy for The Treatment of High-risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Renaissance Pharma

    Menu

    Renaissance Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Renaissance Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Essential Pharma Acquires Renaissance Pharma Ltd with its Clinical Stage Immunotherapy for The Treatment of High-risk Neuroblastoma

              Details:

              Through the acquisition, Essential Pharma will leverage Renaissance clinical-stage immunotherapy product Hu14.18 (Hu14.18K322A) for the treatment of high-risk neuroblastoma.

              Lead Product(s): Hu14.18K322A

              Therapeutic Area: Oncology Product Name: Hu14.18

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Essential Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition April 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Renaissance Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Renaissance Pharma Launches Today and Announces the In-Licensing of Hu14.18K322A (Hu14.18) from St. Jude Children™s Research Hospital for the Treatment of High-Risk Neuro...

              Details:

              Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

              Lead Product(s): Dinutuximab

              Therapeutic Area: Oncology Product Name: Hu14.18K322A

              Highest Development Status: Phase II Product Type: Large molecule

              Recipient: St. Jude Children’s Research Hospital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY